ArticleDermatology and therapy2026
Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.American journal of clinical dermatology · 2026Review
- Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, has demonstrated efficacy and safety in phase III trials for moderate-to-severe atopic dermatitis (AD). However, long-term real-world evidence, particularly in European populations and in difficult-to-treat areas such as the head and neck, remains limited. This study evaluated the 52-week real-world effectiveness and safety of lebrikizumab in patients with moderate-to-severe AD.
methodsThis retrospective, two-center study included adults and adolescents treated with lebrikizumab according to the approved label. Clinical assessments were performed at baseline and weeks 16, 24, and 52. Effectiveness outcomes included the Eczema Area and Severity Index (EASI) 75/90/100, absolute EASI thresholds, Investigator's Global Assessment (IGA) 0/1, patient-reported outcomes (Peak Pruritus Numerical Rating Scale [PP-NRS] and Sleep Disturbance Numerical Rating Scale [S-NRS]), and minimal disease activity (MDA) defined as the combined endpoint EASI 90 plus PP-NRS 0/1. Head and neck involvement was specifically analyzed. Safety was assessed by recording adverse events (AEs).
resultsA total of 123 patients were included (116 adults, 7 adolescents). EASI 75 was achieved by 65.0%, 68.9%, and 82.6% of patients at weeks 16, 24, and 52, respectively. EASI 90 increased from 43.9% at week 16 to 69.6% at week 52, while EASI 100 was observed in 56.5% at week 52. IGA 0/1 was achieved by 82.6% of patients at week 52. Clinically meaningful pruritus improvement (ΔPP-NRS ≥ 4) was observed in 65.2% of patients at week 52, and MDA was achieved by 56.6%. Patients with head and neck AD showed comparable clinical responses to those without involvement of this area, with a marked reduction in head and neck EASI (H&N EASI) over time. Overall, 5.7% of patients reported at least one AE, most commonly mild-to-moderate conjunctivitis, with no new safety signals.
conclusionsIn this real-world European cohort, lebrikizumab demonstrated sustained effectiveness and a favorable safety profile over 52 weeks, including in patients with head and neck involvement, supporting its long-term use in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.